At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 481 enrolled
Drug / intervention
Placebo nasal spray +1 moredrug
Likely dose
0.15% azelastine hydrochloride Nasal Spray 822 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Double Blind, Placebo-Controlled Trial of the Safety and Efficacy of MP03-036 in Patients With Seasonal Allergic Rhinitis
In Brief
A Phase 3 clinical trial evaluating Placebo nasal spray and 0.15% azelastine hydrochloride Nasal Spray for Seasonal Allergic Rhinitis. Completed, enrolled 481 participants across 34 sites.
Detailed Summary
The Purpose of this study is to determine if one allergy medication (0.15% azelastine hydrochloride) is more effective than Placebo alone
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeasonal Allergic Rhinitis
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2007
Primary CompletionNov 2007
First PostedJul 2008
TodayJul 2026
First PostedJul 22, 2008
Enrollment StartAug 1, 2007
Primary CompletionNov 1, 2007
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 17.9 years ago
Interventions
Placebo nasal spraydrug
Placebo
0.15% azelastine hydrochloride Nasal Spraydrug
0.15% azelastine hydrochloride 822 mcg